Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyTargeting the Checkpoint to Kill Cancer CellsImproving the efficacy of chemoradiation with targeted agentsEmerging Treatment Paradigms in Radiation OncologyChemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promisingStructure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapiesMolecular pathways: targeting the dependence of mutant RAS cancers on the DNA damage responsePerspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancerImproving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordThe cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial designCentromere fragmentation is a common mitotic defect of S and G2 checkpoint override.Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell deathRe-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpointsCHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cellsThe Mre11 nuclease is critical for the sensitivity of cells to Chk1 inhibition.DNA-damage response during mitosis induces whole-chromosome missegregationTargeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapyMonitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.PV1 down-regulation via shRNA inhibits the growth of pancreatic adenocarcinoma xenografts.Differential regulation of p21 (waf1) protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications.Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family.Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress.Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder.Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cellsCHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.Cell cycle proteins as promising targets in cancer therapyThe Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy
P2860
Q26745686-73A7AAA2-9E92-4F77-9CC3-DA94A716D24FQ26795781-3F8D3C4F-22F0-4206-BBFE-F50710DC2FB4Q26850193-6AD5C8A2-6665-4B37-B412-8FF9D9D5F8A0Q26853461-693DD366-5BFF-4BCA-BBD8-35DFD2063A14Q26863501-FD87ECF5-7324-4B0C-83FA-7DE59A285B21Q26864870-CEB43599-7BAB-454B-A242-02EAF4B3F6DBQ27014080-D6F8FF09-7F1B-4433-902A-42E20995632AQ28066320-F8581644-8F55-4475-BD59-37555879D346Q28077848-48B700AD-53D7-403C-B98A-854D02D81B9AQ28078268-0916333E-8AA3-43A9-B108-B98325E809B5Q28289090-0FA36196-D49C-4D7C-B701-821561E2F945Q30540593-AFA35D28-71E8-4152-9179-D222BE43A8FCQ30570001-16E2D355-00FF-4D17-9A2A-7CFB63B93386Q30584974-B8212587-A467-47CA-9801-C4EDB00E0C23Q33815609-0AFAD519-CEAC-446A-9841-CF5FB89D9050Q34399650-B45E6056-56C5-480C-B2CC-C5D76344AEE6Q34458357-455229B3-5E36-4DC5-974E-32FB5C1BD8FCQ34654741-2D5A9D34-C7D6-44DE-832C-E250F1FD9B56Q35039916-8B6F027F-4113-4E8E-85AD-D742B06A2B3BQ35073758-048F666A-8CBC-47DA-B3BA-65C397954085Q36189324-18724741-B56D-4575-A978-811DA29FC074Q36213620-2057934B-059C-463A-ADEE-1ABE22FF6843Q36289902-497D4DAB-A381-4415-BEB7-5D46C3D3334EQ36405766-D3D92FCF-4799-471D-91AA-83C9E2B202E5Q36545022-71E221DF-26D8-4454-BA34-D9E0DA3F19F2Q36545701-68B01D85-B0C2-46A0-B462-2932FAFE3E2AQ36546455-5A6421BC-4D1C-4879-B19A-CFAD6D6E1DF9Q36738836-5B7AC45A-C2DE-4F63-8AC8-5EBB3FB7A7BFQ36771796-B834407F-6058-4B62-B63A-AC827BBEC753Q36792626-6FC7569C-D362-4756-81D3-97D19AC3109AQ36927012-275DE719-E071-4286-B35C-7026303EAACEQ36941455-1A401AE2-E78F-4459-85E0-A47E8994F235Q37100166-0AD25D0A-5CAF-4262-A7ED-CA54EFE1B48EQ37376369-F4F87C99-8CB2-461B-BAD0-32439AF52E6CQ37564392-CAEA62FE-E257-40B8-AF41-E5ED5ECE3418Q37638784-3527B0C0-83D5-4313-BE75-E1C0E61836D9Q37641736-403CE804-A6A1-4151-AF9B-B65CCA1D7EFEQ37676283-6C8FBC07-247C-461F-A781-66FA8E27EE5FQ37693690-E72344ED-21F9-47BF-9F4F-15C2F898C972Q37744731-6C2CB6B5-13E5-4161-A3F0-BE92EF22323C
P2860
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Preclinical development of the ...... ng agents and antimetabolites.
@ast
Preclinical development of the ...... ng agents and antimetabolites.
@en
type
label
Preclinical development of the ...... ng agents and antimetabolites.
@ast
Preclinical development of the ...... ng agents and antimetabolites.
@en
prefLabel
Preclinical development of the ...... ng agents and antimetabolites.
@ast
Preclinical development of the ...... ng agents and antimetabolites.
@en
P2093
P2860
P1476
Preclinical development of the ...... ng agents and antimetabolites.
@en
P2093
Alan Eastman
David Parry
Injae Chung
Kristen M Garner
Ryan Montano
P2860
P304
P356
10.1158/1535-7163.MCT-11-0406
P577
2011-12-27T00:00:00Z